R&D activities focus on the development of new technologies, products and services that ensure safe blood transfusion and transplantation, on new cell and tissue therapies, and on improving diagnostics. Efficient use of cells and their products has become the foundation for new advanced treatments. Fast developing cell therapies and regenerative medicine require new, innovative approaches to prepare high-tech therapeutic products with high added value that improve the quality of patients' lives. Our research activities relate to medical and natural sciences as well as biotechnology, they fall within the scope of basic and applied research, and form a part of our employees' continuous training.


BTC has been Registryed as a research organisation since 1953, under code 0311.